Next 10 |
home / stock / dgx / dgx articles
Bond appetites are growing as more and more investors look to lock in high-yielding assets ahead of an expected decline in interest rates this year...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
The CNN Money Fear and Greed index showed a sharp decline in the overall market sentiment, while the index remained in the "Greed" zone o...
A new era in Alzheimer’s diagnosis is on the horizon as Dr. Suzanne Schindler and her team at Washington University School of Medic...
Consulting giant McKinsey & Co, on Friday, agreed to a settlement of $78 million to resolve allegations tied to the opioid epidemic, as di...
Truist Securities analyst David S. MacDonald reiterated a Hold rating on Quest Diagnostics Incorporated (NYSE: DGX), raising th...
The U.S. Supreme Court is set to deliberate on the future of mifepristone, a crucial drug employed in over half of all abortions within the U.S.&nb...
Quest will provide research consulting, laboratory testing and data analytics services to generate diagnostics insights supporting population healt...
The U.S. Supreme Court is reviewing a contentious bankruptcy settlement involving Purdue Pharma, the maker of OxyContin, and its owners, the&n...
News, Short Squeeze, Breakout and More Instantly...
Quest Diagnostics Incorporated Company Name:
DGX Stock Symbol:
NYSE Market:
NORTHAMPTON, MA / ACCESSWIRE / March 26, 2024 / Quest Diagnostics At Quest for 2 years, Marissa McGhee , Patient Services Representative (PSR 1) in Stamford, Connecticut, has grown to have a bit of a local following amongst some patients. Recently, one of those patients shared their experie...
Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease PR Newswire Findings suggest the test can reduce the need for PET imaging in some patients with mild cognitive decline to enable thera...
2024-03-20 14:30:02 ET Truist Financial analyst issues MARKET PERFORM recommendation for DGX on March 20, 2024 12:00PM ET. The previous analyst recommendation was Market Perform. DGX was trading at $128.43 at issue of the analyst recommendation. The overall analyst conse...